Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication FRAGMIN is a low molecular weight heparin (LMWH) indicated for • Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction ( 1.1 ) • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness ( 1.2 ) • Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the… FDA label
dalteparin · 1 trial · 1 indication
Prespecified therapeutic anti-factor Xa level was 0.5-1.0 international unit per milliliter (IU/mL). Cumulative data of Day 1 to 7 has been reported.
| Arm | Type | Description |
|---|---|---|
| Single Arm | OTHER | Single arm open-label |
| Name | Type | Description |
|---|---|---|
| dalteparin | DRUG | dalteparin subcutaneous injection |
Inclusion Criteria: \- Exclusion Criteria: \-
Dalteparin is being studied for the treatment of venous thromboembolism, including in pediatric cancer patients. It is an anticoagulant developed by Pfizer, Inc. under the ticker PFE. The research focuses on managing acute VTE in this specific patient population.
Dalteparin targets SERPINC1, also known as antithrombin III. It acts as an activator of this target. By activating antithrombin, dalteparin enhances the inhibition of thrombin and factor Xa, which are key enzymes in the blood clotting cascade.
Dalteparin is developed by Pfizer, Inc., which trades under the ticker symbol PFE. Pfizer is a global pharmaceutical company involved in the research and development of various therapeutic products.
Dalteparin is in Phase 2 clinical development for venous thromboembolism. It is an investigational drug and has not been approved by the FDA for this indication. The Phase 2 trial has been completed.
Dalteparin has been studied in a completed Phase 2 trial, NCT00952380, titled "Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients." This trial enrolled 38 participants and was conducted in the United States, Norway, Russia, Slovenia, and Spain.